Cargando…

Responses to crizotinib and disease monitoring with circulating tumor cells in lung adenocarcinoma patient with MET exon 14 skipping mutation: A case report

RATIONALE: Mesenchymal-to-epithelial transition (MET) exon 14 skipping mutation was a targetable alteration in nonsmall-cell lung cancer (NSCLC), and the MET inhibitor of crizotinib had the most efficacy among all the targeted drugs. Most of the cancer-related deaths are associated with metastasis....

Descripción completa

Detalles Bibliográficos
Autores principales: Tan, Xiang, Dai, Lei, Wang, Yongyong, Liang, Guanbiao, Yang, Nuo, Chen, Mingwu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5708966/
https://www.ncbi.nlm.nih.gov/pubmed/29381967
http://dx.doi.org/10.1097/MD.0000000000008744
_version_ 1783282713167396864
author Tan, Xiang
Dai, Lei
Wang, Yongyong
Liang, Guanbiao
Yang, Nuo
Chen, Mingwu
author_facet Tan, Xiang
Dai, Lei
Wang, Yongyong
Liang, Guanbiao
Yang, Nuo
Chen, Mingwu
author_sort Tan, Xiang
collection PubMed
description RATIONALE: Mesenchymal-to-epithelial transition (MET) exon 14 skipping mutation was a targetable alteration in nonsmall-cell lung cancer (NSCLC), and the MET inhibitor of crizotinib had the most efficacy among all the targeted drugs. Most of the cancer-related deaths are associated with metastasis. Circulating tumor cells (CTCs) have been a valuable biomarker in assessing metastasis. Recent experiences suggested that CTCs detection may help improve diagnosis and predict prognosis for patients with NSCLC. However, few literatures have reported the CTCs detection based on the (MET) exon 14 skipping, which are positive in NSCLC patients. PATIENT CONCERNS: The patient, a 69-year-old Chinese male, with a 50 years history of smoking. Because of the cough, the patient went to the hospital and found the upper right lung tumor and the right supraclavicular lymph node enlarged. He was worried that it was cancer. DIAGNOSES: The patient was performed biopsy of the right clavicle lymph node metastasis on October 12 and sent the tissue specimen for pathological evaluation. Finally, the patient was diagnosed to be with a pT3N3Mx stage IIIC lung adenocarcinoma. INTERVENTIONS: The patient began to take orally crizotinib 250 mg twice a day for the medical therapy after lymph node biopsy. At the same time, the CTCs were detected to observe the prognosis of the patients. OUTCOMES: Compared with the first CTCs result, the second test revealed a decrease in the amount of CTCs, while the mesenchymal CTCs have increased, indicating the possibility of distal metastasis. LESSONS: This is the first proof that CTCs can be quantitatively assayed by MET exon 14 skipping mutation, which demonstrates the clinical response to crizotinib. More cases should be reported and further evaluation for treatment options and prognosis evaluation is necessary.
format Online
Article
Text
id pubmed-5708966
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-57089662017-12-07 Responses to crizotinib and disease monitoring with circulating tumor cells in lung adenocarcinoma patient with MET exon 14 skipping mutation: A case report Tan, Xiang Dai, Lei Wang, Yongyong Liang, Guanbiao Yang, Nuo Chen, Mingwu Medicine (Baltimore) 5700 RATIONALE: Mesenchymal-to-epithelial transition (MET) exon 14 skipping mutation was a targetable alteration in nonsmall-cell lung cancer (NSCLC), and the MET inhibitor of crizotinib had the most efficacy among all the targeted drugs. Most of the cancer-related deaths are associated with metastasis. Circulating tumor cells (CTCs) have been a valuable biomarker in assessing metastasis. Recent experiences suggested that CTCs detection may help improve diagnosis and predict prognosis for patients with NSCLC. However, few literatures have reported the CTCs detection based on the (MET) exon 14 skipping, which are positive in NSCLC patients. PATIENT CONCERNS: The patient, a 69-year-old Chinese male, with a 50 years history of smoking. Because of the cough, the patient went to the hospital and found the upper right lung tumor and the right supraclavicular lymph node enlarged. He was worried that it was cancer. DIAGNOSES: The patient was performed biopsy of the right clavicle lymph node metastasis on October 12 and sent the tissue specimen for pathological evaluation. Finally, the patient was diagnosed to be with a pT3N3Mx stage IIIC lung adenocarcinoma. INTERVENTIONS: The patient began to take orally crizotinib 250 mg twice a day for the medical therapy after lymph node biopsy. At the same time, the CTCs were detected to observe the prognosis of the patients. OUTCOMES: Compared with the first CTCs result, the second test revealed a decrease in the amount of CTCs, while the mesenchymal CTCs have increased, indicating the possibility of distal metastasis. LESSONS: This is the first proof that CTCs can be quantitatively assayed by MET exon 14 skipping mutation, which demonstrates the clinical response to crizotinib. More cases should be reported and further evaluation for treatment options and prognosis evaluation is necessary. Wolters Kluwer Health 2017-11-27 /pmc/articles/PMC5708966/ /pubmed/29381967 http://dx.doi.org/10.1097/MD.0000000000008744 Text en Copyright © 2017 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nd/4.0 This is an open access article distributed under the Creative Commons Attribution-NoDerivatives License 4.0, which allows for redistribution, commercial and non-commercial, as long as it is passed along unchanged and in whole, with credit to the author. http://creativecommons.org/licenses/by-nd/4.0
spellingShingle 5700
Tan, Xiang
Dai, Lei
Wang, Yongyong
Liang, Guanbiao
Yang, Nuo
Chen, Mingwu
Responses to crizotinib and disease monitoring with circulating tumor cells in lung adenocarcinoma patient with MET exon 14 skipping mutation: A case report
title Responses to crizotinib and disease monitoring with circulating tumor cells in lung adenocarcinoma patient with MET exon 14 skipping mutation: A case report
title_full Responses to crizotinib and disease monitoring with circulating tumor cells in lung adenocarcinoma patient with MET exon 14 skipping mutation: A case report
title_fullStr Responses to crizotinib and disease monitoring with circulating tumor cells in lung adenocarcinoma patient with MET exon 14 skipping mutation: A case report
title_full_unstemmed Responses to crizotinib and disease monitoring with circulating tumor cells in lung adenocarcinoma patient with MET exon 14 skipping mutation: A case report
title_short Responses to crizotinib and disease monitoring with circulating tumor cells in lung adenocarcinoma patient with MET exon 14 skipping mutation: A case report
title_sort responses to crizotinib and disease monitoring with circulating tumor cells in lung adenocarcinoma patient with met exon 14 skipping mutation: a case report
topic 5700
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5708966/
https://www.ncbi.nlm.nih.gov/pubmed/29381967
http://dx.doi.org/10.1097/MD.0000000000008744
work_keys_str_mv AT tanxiang responsestocrizotinibanddiseasemonitoringwithcirculatingtumorcellsinlungadenocarcinomapatientwithmetexon14skippingmutationacasereport
AT dailei responsestocrizotinibanddiseasemonitoringwithcirculatingtumorcellsinlungadenocarcinomapatientwithmetexon14skippingmutationacasereport
AT wangyongyong responsestocrizotinibanddiseasemonitoringwithcirculatingtumorcellsinlungadenocarcinomapatientwithmetexon14skippingmutationacasereport
AT liangguanbiao responsestocrizotinibanddiseasemonitoringwithcirculatingtumorcellsinlungadenocarcinomapatientwithmetexon14skippingmutationacasereport
AT yangnuo responsestocrizotinibanddiseasemonitoringwithcirculatingtumorcellsinlungadenocarcinomapatientwithmetexon14skippingmutationacasereport
AT chenmingwu responsestocrizotinibanddiseasemonitoringwithcirculatingtumorcellsinlungadenocarcinomapatientwithmetexon14skippingmutationacasereport